We recently published a list of 12 Best Quality Stocks to Invest in Now. In this article, we are going to take a look at ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

The exact price depends on dosage, pharmacy, location, insurance coverage, and available savings programs. Fully ...

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...

Zeroing in on Eli Lilly, the company is already well established with Zepbound, which should continue to sell briskly as the world waits for a more powerful and efficacious obesity drug to hit the ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...

A federal judge ended compounding pharmacies’ ability to make copies of the weight loss and diabetes drugs Zepbound and ...